Poststroke spasticity is a motor condition causing muscle stiffness and involuntary contractions that may result from damage to the brain following a stroke. In this article, David M. Simpson, MD, discusses the safety and effectiveness of botulinum toxin type A in the treatment of poststroke spasticity.
Selecting appropriate treatment for patients with multiple sclerosis (MS) is challenging because the many disease-modifying therapy (DMT) options can have different effects on different people. In this article, Anne Cross, MD, professor of neurology at Washington University School of Medicine in Missouri, discusses guiding patients through DMT options for MS.
The treatment for multiple sclerosis (MS) has traditionally involved escalating therapies from a moderate-efficacy disease-modifying therapy (DMT) to a higher-efficacy DMT when breakthrough disease activity occurs. In this article, Yinan Zhang, MD, assistant professor of neurology at the Ohio State University Wexner Medical Center in Columbus, Ohio, discusses the benefits, risks, and importance of DMTs for MS.
Post-stroke spasticity (PSS) can significantly impair a patient’s motor function and quality of life, especially when affecting the lower limbs. Parneet K. Grewal, MD, clinical assistant professor of neurology at the Medical University of South Carolina in Charleston, discusses the management of PSS in adult patients using botulinum toxin type A.
Many factors can influence the selection of disease modifying therapies (DMTs) in patients with relapsing multiple sclerosis (MS), such as efficacy and administration frequency. In this article, Yinan Zhang, MD, the assistant professor of neurology at the Ohio State University Wexner Medical Center in Columbus, Ohio, discusses several ways physicians can help reduce the burden associated with DMTs for patients with relapsing MS.
Robert Bermel, MD, is a staff neurologist at the Neurological Institute’s Mellen Center for Multiple Sclerosis at Cleveland Clinic in Ohio. In this article, Dr Bermel discusses self-injectable disease-modifying therapies in multiple sclerosis.
Reviewed September 2022
Choosing a first-line disease-modifying therapy (DMT) for the treatment of multiple sclerosis (MS) can be challenging due to the clinical diversity of the disease, the number of DMTs available, and patient preferences. Clinician and patient priorities for switching therapy can differ, but patient preference must be a major consideration because it affects adherence to treatment.
Disease-modifying therapies can reduce multiple sclerosis relapse rates. Jonathan E. Howard, MD, a neurologist and associate professor of neurology and psychiatry at
NYU Grossman School of Medicine provides insight on factors that contribute to switching disease modifying therapies in MS due to breakthrough disease activity or inadequate response to therapy.
Christoph U. Correll, MD, professor of psychiatry and molecular medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and medical director of the Recognition and Prevention (RAP) program at Zucker Hillside Hospital, discusses how 2 new VMAT2 agents are changing the management of tardive dyskinesia.
Amos Katz, MD, a board-certified neurologist, discusses the role and benefit of initiating appropriate early disease-modifying therapy to delay disability progression in patients with multiple sclerosis.
Jonathan L. Carter, MD, neuromuscular disease specialist and associate professor of neurology at the Mayo Clinic Alix School of Medicine, Phoenix/Scottsdale, Arizona, discusses the clinical utility of CD20-targeted B-cell therapy for relapsing forms of multiple sclerosis.
The transition from relapsing-remitting multiple sclerosis to secondary progressive disease can be easily missed. Neurologist and clinical researcher Mark S. Freedman, MD, CSPQ, FANA, FAAN, FRCPC, discusses the assessment and management of disease progression in relapsing forms of multiple sclerosis.
Fatigue is one of the most frequently reported symptoms in people with MS; however, its etiology and presentation can vary from patient to patient. In this interview, approaches to identifying fatigue and a team-based strategy for minimizing its impact on patients’ lives are discussed.
Please login or register first to view this content.